Mostrando las entradas con la etiqueta Musculoskeletal Disorders. Mostrar todas las entradas
Mostrando las entradas con la etiqueta Musculoskeletal Disorders. Mostrar todas las entradas

20 junio, 2013

Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent:

Rheumatoid arthritis jointImage via Wikipedia
Salliot C, Finckh A, Katchamart W, et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis. 2011 Feb;70(2):266-71. Epub 2010 Nov 19. (Review) PMID: 21097801
Read Abstract Read Full Text
Clinical Evidence Topic: Rheumatoid arthritis







Abstract
BACKGROUND: The availability of increasing numbers of biological agents for the treatment of rheumatoid arthritis (RA) offers several therapeutic options. While all biologicals have proven effective in trials, very limited direct comparisons are available. The objective of the present work was to compare the efficacy of biologicals (anti-tumour necrosis factor (TNF) agents, rituximab, abatacept, tocilizumab) in patients with RA with active disease and (i) an inadequate response (IR) to methotrexate (IR-MTX), (ii) an IR to anti-TNF agents (IR-anti-TNFs) using indirect comparisons.
METHODS: Randomised clinical trials were identified examining the efficacy of a biological agent in RA at 6 months in patients with an IR-MTX or with an IR-anti-TNF. To compare the relative efficacy of biologicals, adjusted indirect comparison meta-analytic methods to estimate the ORs of achieving a 50% improvement according to American College of Rheumatology criteria (ACR50) response at 6 months were used.
RESULTS: A total of 18 published trials and 1 abstract were included in the analyses. In IR-MTX, anti-TNFs had the same probability of reaching an ACR50 compared to `non-anti-TNF biologicals` taken together (OR 1.30, 95 % CI 0.91 to 1.86). However, when compared to specific biological agents, anti-TNFs demonstrated a higher probability of reaching an ACR50 than abatacept (OR 1.52, 95 % CI 1.0 to 2.28), but not in comparison to rituximab and tocilizumab. In IR-anti-TNF, rituximab demonstrated a higher probability of achieving an ACR50 than tocilizumab (OR 2.61, 95% CI 1.10 to 6.37), but no significant differences existed between rituximab, tocilizumab, abatacept and golimumab.
CONCLUSIONS: In a meta-analysis of randomised clinical trials of patients with IR-MTX, anti-TNFs demonstrated a higher probability of achieving an ACR50 response than abatacept. In IR-anti-TNF, no difference was found between rituximab, tocimizumab, abatacept and golimumab.

Enhanced by Zemanta

10 mayo, 2013

Eficacia de bazedoxifeno en la reducción del riesgo de nuevas fracturas vertebrales en mujeres posmenopáusicas.

File: Osteoporosis-international-179x237.jpg
File: Osteoporosis-international-179x237.jpg (Photo credit: Wikipedia)
Via: Galo Sanchez 
Miguel Ángel Martín de la Nava[1] ha hecho el resumen de una evaluación GRADE del ensayo clínico 300-WW, que hemos puesto a disposición de los interesados en la web de la Oficina (evalmed.es), en la pestaña “FORMACIÓN”, cuyas recomendaciones (válidas para este estudio) se recuadran más abajo.


Estudio 300-WW: Eficacia de bazedoxifeno en la reducción del riesgo de nuevas fracturas vertebrales en mujeres posmenopáusicas.

Silverman SL, Christiansen C, Genant HK. Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Posmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial. J Bone Miner Res 2008;23:1923–34.

Los resultados que más importan a las mujeres posmenopáusicas con un diagnóstico de osteoporosis son las fracturas del cuello del fémur (también llamadas de cadera), por la morbimortalidad asociada, y las fracturas vertebrales clínicas.
     El estudio 300-WW pretende evaluar la eficacia y seguridad de bazedoxifeno frente a raloxifeno y frente a placebo en la prevención de fracturas vertebrales y no vertebrales.

RECOMENDACIONES GRADE (VÁLIDAS PARA ESTE ESTUDIO)


Justificación:

A) BENEFICIOS Y RIESGOS AÑADIDOS: Frente a placebo, tanto bazedoxifeno como raloxifeno no muestran beneficios en fracturas de cuello de fémur (llamadas de cadera), fracturas NO vertebrales totales, fracturas vertebrales clínicas, morbimortalidad cardiovascular, ni carcinoma de mama o endometrio. Únicamente muestran beneficio significativo en las fracturas vertebrales totales, si bien a expensas de las “subclínicas”.
                En riesgos añadidos se asocian con más trombosis venosa profunda (aunque sus NND son de magnitud de efecto muy baja), sofocos (mayoritariamente leves o moderados) y calambres en las piernas.

B) INCONVENIENTES: Tomar una pastilla diaria.

C) COSTES: Coste/día: RALO-60: 0,74 €/día (270 €/año) y BAZE-20: 1,23 €/día (449 €/año).
                Acudiendo a los intervalos de confianza del NNT, el coste económico de la prevención de una fractura vertebral (a expensas de las subclínicas) con BAZE-20, en las condiciones de este ensayo clínico, estaría entre 46.048 y 254.363 euros en 3 años, y con RALO-60 entre 27.690 y 152.958 euros en 3 años. No incluimos los costes de la asistencia médica ni de las pruebas diagnósticas, porque excede del objetivo de esta evaluación.


[1] Miguel Ángel Martín de la Nava. Farmacéutico de Atención Primaria. Centro de Salud de Zorita (Cáceres)

01 octubre, 2011

Osteoporosis: Las guías de la discordia

Las guías de la discordia
Maria Valerio. El Mundo (España) 12/11/2010
http://tinyurl.com/Mac-guia-osteo




Un documento de consenso avalado por el Ministerio de Sanidad y Consumo y la Generalitat de Cataluña sobre el tratamiento de la osteoporosis ha desatado la polémica en la Red. Algunos de los autores que aparecen como revisores del texto han mostrado su descontento con la versión final y muchos especialistas critican el 'abuso' de los fármacos que promueve.


El doctor Rafael Bravo, especialista en Atención Primaria, fue el primero en soltar la liebre desde su blog al criticar la "dudosa calidad científica" de la llamada Guía de Práctica Clínica sobre Osteoporosis y Prevención de Fracturas por Fragilidad .


A su juicio, el manual apuesta por tratar preventivamente a mujeres postmenopáusicas, sin factores de riesgo, con el objetivo de prevenir supuestamente la aparición de fracturas y empleando unos fármacos (como los bifosfonatos o el raloxifeno) no exentos de riesgo. "Erróneamente se iguala menopausia, osteoporosis y tratamiento farmacológico", explica este experto a ELMUNDO.es.
La osteoporosis es una pérdida de la densidad ósea relacionada con la caída de estrógenos que sufren las mujeres en la menopausia. Como recogen los Institutos Nacionales de Salud de EEUU, el tratamiento está reservado para los casos ya diagnosticados (por medio de un estudio que mide la densidad del hueso) o bien para mujeres con osteopenia (una fase previa a la osteoporosis en la que los huesos están debilitados), pero que ya han sufrido una fractura.


Descontento
Bastó una entrada en su blog, para que algunos de los especialistas que presuntamente habían revisado el documento de 'consenso' manifestaran su sorpresa y su disconformidad con la versión final. Es el caso de Cecilia Calvo, del servicio balear de salud y miembro de la Sociedad Española de Farmacia Hospitalaria. "En mayo de 2009 enviamos los comentarios a un primer borrador del texto y desde entonces no hemos vuelto a saber nada más", se queja. "Hasta que hemos visto nuestro nombre en la publicación final, sin tener en cuenta nuestras consideraciones".
Oriol Solá-Morales, director de Evaluación de la Agència d'Informació, Avaluació i Qualitat en Salut (AIAQS) de Cataluña, el organismo encargado de elaborar la guía a petición del Ministerio, tiene su propia versión de los hechos. "Sabíamos que la osteoporosis es un terreno pantanoso y todo este ruido transmite la idea de que hacía falta una guía; aunque seguramente ésta sea mejorable", admite.
A su juicio, toda esta polémica enfrenta a las dos "posturas" que existen en torno a la osteoporosis "sobre si el tratamiento previene o no las facturas".
De los 15 revisores a quienes se les envió el texto, un 25% de ellos lo devolvió con "cambios mayores" lo que provocó que se incluyeran algunas modificaciones en la versión definitiva que se ha publicado, "pero no es posible incorporar todas las sugerencias porque si no tendríamos que iniciar otra vez el proceso de validación de la evidencia".
Solá-Morales también despeja cualquier duda sobre el papel que haya podido tener la industria farmacéutica en su elaboración: "No conoció el documento hasta que éste se publicó". La agencia ha emitido una nota en la que confirma que 22 de los 25 revisores han aceptado finalmente constar en la versión final de la guía.
Cecilia Calvo recuerda que los fármacos para prevenir las fracturas son más útiles en las mujeres de mayor riesgo, "aunque la guía es muy laxa en este sentido y menciona cualquier medicamento que haya demostrado cualquier cosa, sin tener en cuenta el balance riesgo-beneficios y sin analizar el impacto económico que puede tener su uso en el sistema nacional de salud". A su juicio, con esta guía, el ministerio avala la medicalización de la menopausia, "creando la sensación de que todo el mundo tiene que tratarse".


La entrada de Rafa en su blog: http://tinyurl.com/Mac-guia-rafa
la Guía sobre Osteoporosis: http://tinyurl.com/Mac-guiabestias






Martin Cañás
Fundación Femeba
Grupo Argentino Para el Uso Racional del Medicamento (GAPURMED)
La Plata (Argentina)


05 noviembre, 2010

Bioabsorbable versus metallic interference screw fixation in anterior cruciate ligament reconstruction: a meta-analysis of randomized controlled trials

Arthroscopic reconstruction of the anterior cr...Image via Wikipedia
Source: Database of Abstracts of Reviews of Effects (DARE)

Bioabsorbable versus metallic interference screw fixation in anterior cruciate ligament reconstruction: a meta-analysis of randomized controlled trials
Shen C, Jiang SD, Jiang LS, Dai LY
CRD summary
The review concluded that there was no significant difference between bioabsorbable and metal screw fixation in terms of knee joint stability and knee function outcomes. Knee joint effusion was more common after anterior cruciate ligament reconstruction with bioabsorbable screw fixation. The review was generally well conducted but limitations of the included trials should be borne in mind.
Authors' objectives
To identify and summarise the evidence on the differences in outcomes between bioabsorbable and metallic screw fixation in anterior cruciate ligament reconstruction.
Searching
PubMed and The Cochrane Library were searched from January 1966 to December 2008. Search terms were reported.
Study selection
Randomised controlled trials (RCTs) or quasi-RCTs of ligamentous reconstruction with single-bundle graft with either bioabsorbable or metal screw fixation in patients who presented with anterior cruciate ligament disruption and needed surgical intervention were eligible for inclusion. Trials had to provide objective measures of clinical outcomes. Trials without comparison of the clinical results (such as case-series and reviews) and trials without an English abstract were excluded.
The included trials, where reported, studied titanium metal screws versus polyglycolic acid (PGA), poly-L-lactic acid (PLLA), trimethylene carbonate (TMC) and PLLA with hydroxyapatite bioabsorbable screws. Graft material included bone-patella tendon-bone (BPTB), quadrupled hamstring tendon, hamstring tendon and Achilles tendon. Time to rehabilitation varied from immediately after surgery to two weeks after surgery. Length of follow-up ranged from 12 to 29 months. All trials were published between 1995 and 2008.
Two authors independently undertook the selection process.
Validity assessment
Quality assessment was undertaken independently by two reviewers using the Detsky 21-point scale to assess quality factors that included randomisation, study design, allocation concealment and analysis method. Disagreements were resolved by referral to a third reviewer.
Data extraction
Two authors independently extracted data on functional outcomes, radiographic outcomes, stability of the knee outcomes and complications. The authors used these data to calculate standardised mean differences (SMDs) for continuous outcomes or relative risks (RRs) for dichotomous outcomes, together with 95% confidence intervals (CIs). Disagreements were resolved by referral to a third reviewer.
Methods of synthesis
Pooled relative risks or SMDs, together with 95% CIs, were calculated using fixed-effect or random-effects meta-analysis. Where pooling was not possible, data were presented as a narrative synthesis. Statistical heterogeneity was assessed using X2 and the I2 statistic. Publication bias was assessed with funnel plot analysis. Subgroup analysis by type of bioabsorbable screw was undertaken.
Results of the review
Ten RCTs were included in the review (n=790 patients). Sample size ranged from 40 to 204. Trial quality varied from 11 out of 21 to 18 out of 21 and six RCTs scored at least 14 out of 21.
Compared with metal screw fixation, bioabsorbable screw fixation did not offer any statistically significant benefits in terms of KT-1000/2000 arthrometer testing (SMD -0.01, 95% CI -0.20 to 0.18, I2=7%; seven RCTs), pivot-shift testing (RR 1.06, 95% CI 0.67 to 1.67, I2=35%; four RCTs), international knee documentation committee final score (RR 0.87, 95% CI 0.51 to 1.51, I2=0%; five RCTs), Lysholm score (SMD 0.03, 95% CI -0.39 to 0.45, I2=54%; four RCTs) and infection rate (RR 0.96, 95% CI 0.30 to 3.13, I2=0%; five RCTs). Compared with metal screw fixation, bioabsorbable screw fixation had a statistically significantly higher incidence of knee effusion (RR 2.57, 95% CI 1.03 to 6.43, I2=0%; four RCTs). Three out of seven trials reported that tunnel widening on the femoral or tibial side was more prominent in patients who received bioabsorbable screw fixation compared with those in the metal screw group; the remaining four trials provided insufficient data.
Results by type of bioabsorbable screw were presented in the review.
Authors' conclusions
There was no significant difference between bioabsorbable and metal screw fixation in terms of knee joint stability and knee function outcomes. Knee joint effusion was more common after anterior cruciate ligament reconstruction with bioabsorbable screw fixation.
CRD commentary
Inclusion criteria for the review were clearly defined. Two relevant databases were searched. There was potential for language bias as only trials with an English-language abstract were included. Publication bias was assessed only when significant heterogeneity was detected and, therefore, could not be ruled out from the analysis completely; there was no attempt to locate unpublished data. Two authors performed study selection, data extraction and quality assessment, which minimised risks of error and bias in the analysis. The quality assessment indicated variable quality of the included trials, which was acknowledged by the authors. There were no details on patient characteristics. The authors acknowledged variability among trials in terms of grafts and implants. Where possible, trials were combined using meta-analysis. Appropriate methods were used to assess statistical heterogeneity. A small number of trials were included in the comparisons and they had small sample sizes. Confidence intervals for some comparisons (for example, incidence of knee effusion) were wide, which questioned the robustness of the findings.
Aside from a somewhat limited literature search, this was generally a well-conducted review. The authors’ conclusions appear to reflect the evidence, but the limitations of the included trials should be borne in mind.
Implications of the review for practice and research
Practice: The authors did not state any implications for practice.
Research: The authors stated that high-quality RCTs with standardised and objective outcome measures were needed. Measurements of quality of life and patient satisfaction should be considered at follow-up.
Funding
Not stated.
Bibliographic detail
Shen C, Jiang SD, Jiang LS, Dai LY. Bioabsorbable versus metallic interference screw fixation in anterior cruciate ligament reconstruction: a meta-analysis of randomized controlled trials. Arthroscopy 2010; 26(5): 705-713
Link to Pubmed record 20434671
URL for original research http://dx.doi.org/10.1016/j.arthro.2009.12.011
Subject index terms status Subject indexing assigned by CRD
Subject index terms Anterior Cruciate Ligament /injuries /surgery; Biocompatible Materials; Bone Screws; Humans; Knee Injuries /surgery
Accession number 12010003464
Database entry date 3 November 2010
Record status
This record is a structured abstract produced by CRD. The original has met a set of quality criteria. Since September 1996 abstracts have been sent to authors for comment. Additional factual information is incorporated into the record. Noted as [A:....].